Xerostomia Therapeutics Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Apotex Inc. and Church & Dwight Co. Inc. | Technavio

The global xerostomia therapeutics market size is expected to grow by USD 133.27 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of 4%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005704/en/

Technavio has announced its latest market research report titled Global Xerostomia Therapeutics Market 2020-2024 (Graphic: Business Wire).

For the Right Perspective & Competitive Insights- Request Free Sample Report on Pandemic Recovery Analysis

Read the 120-page report with TOC on "Xerostomia Therapeutics Market Analysis Report by Product (OTC and Prescription) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024". Gain competitive intelligence about market leaders. Track key industry opportunities, trends and threats. Information on marketing, brand, strategy and market development, sales and supply functions. https://www.technavio.com/report/xerostomia-therapeutics-market-industry-analysis

Xerostomia therapeutics market is driven by the increasing awareness of xerostomia. In addition, the growing focus on biologics is anticipated to boost the growth of the Xerostomia Therapeutics Market.

Xerostomia can be a symptom of various medical conditions or a side effect of radiation therapy to the head and neck areas. Hence, patients also need to be aware and proactive while speaking to their doctors about the signs and symptoms of xerostomia. Quick diagnosis of xerostomia is crucial due to the risk factors and symptoms of the condition. Additionally, the early detection of the condition can aid in treating xerostomia more effectively. Therefore, various government and non-government organizations are creating awareness about xerostomia with the aim of preventing delays in the diagnosis and overcoming the lack of awareness of treatment. In countries such as the US, the Oral Cancer Foundation is creating awareness about the common causes for and the complications associated with xerostomia, as well as the signs and symptoms, diagnosis and evaluation of the condition and the available treatment options. Thus, the increasing awareness of xerostomia is expected to drive the growth of the market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Xerostomia Therapeutics Companies:

Apotex Inc.

Apotex Inc. offers more than 300 generic pharmaceuticals in approximately 4000 dosages. These include injectables, unit dose products, and specialty products. The company offers Cevimeline hydrochloride tablets, which are used for the treatment of dry mouth in patients with Sjogrens syndrome.

Church & Dwight Co. Inc.

Church & Dwight Co. Inc. has business operations under three segments: consumer domestic, consumer international, and specialty products division. The company offers a gel for the treatment of dry mouth in patients.

Colgate-Palmolive Co.

Colgate-Palmolive Co. operates its business through two segments: oral, personal and home care; and pet nutrition. The company's key offerings include Colgate Hydris dry mouth and Colgate Hydris Hydrating Oral Rinse.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is involved in the acquisition, development, and commercialization of specialty pharmaceutical products. The company offers Ethyol, or amifostin injection, for the treatment of xerostomia that can occur in patients receiving radiation treatment for head and neck cancer.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. has business operations under four segments: innovative pharmaceuticals, generic, vaccine, and OTC related. The company offers EVOXAC, or cevimeline hydrochloride which belongs to a class of drugs known as cholinergic agonists. It works by stimulating certain nerves to increase the amount of saliva, making it easier and more comfortable to speak and swallow.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Xerostomia Therapeutics Market Product Outlook (Revenue, USD mn, 2020-2024)

• OTC - size and forecast 2019-2024
• Prescription - size and forecast 2019-2024

Xerostomia Therapeutics Market Regional Outlook (Revenue, USD mn, 2020-2024)

• North America - size and forecast 2019-2024
• Europe - size and forecast 2019-2024
• Asia - size and forecast 2019-2024
• ROW - size and forecast 2019-2024

Are you a start-up willing to make it big in the business? Grab an exclusive Report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005704/en/